BSE filing, NSE: FREDUN. Summary written from the filing by ALFA Finder's alert engine.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,471.70
- Market cap
- ₹2,109 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 48.1×Sector 46.1×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals allotted 1,82,400 equity shares upon the conversion of 60,800 warrants. The company received total consideration of ₹7.60 Crore for this warrant conversion.
- Value
- ₹7.60 Cr
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals has allotted 1,82,400 equity shares following the conversion of 60,800 warrants into equity shares, completing the preferential issue conversion process.
Other bonus issue announcements
All →Shreeji Global FMCG Bonus Issue
Shreeji Global FMCG board recommended a 1:1 bonus issue funded from securities premium, with no cash paid. Paid-up capital rises from Rs.22.76 Crore to Rs.49.92 Crore.
Concord Biotech Bonus Issue
Concord Biotech fixed 4 November 2026 as the record date for a 1:1 bonus issue, with deemed allotment on 5 November 2026. The bonus is subject to statutory and regulatory approvals.
Anlon Technology Solutions Bonus Issue
Anlon Technology Solutions fixed 02-Nov-2026 as the record date for its 2:5 bonus issue of equity shares. The bonus is free shares from reserves, with no cash paid.
Concord Biotech Bonus Issue
Concord Biotech's postal ballot approved a bonus issue and an authorised capital increase. No cash is paid and no ratio is stated.
Titan Biotech Bonus Issue
Titan Biotech allotted 1,03,29,625 bonus shares of Rs. 2 each in a 1:4 ratio. Paid-up capital rose to Rs. 10.33 Crore post-allotment.
Utssav CZ Gold Jewels Bonus Issue
Utssav CZ Gold Jewels' board recommended a 1:1 bonus issue from free reserves on 23 October 2026. Paid-up capital rises from Rs.25.00 Crore to Rs.50.00 Crore, subject to AGM/postal ballot on 25 November 2026.